Meeting
2023 ASCO Annual Meeting
ECOG-ACRIN LUNG-MAP S1900E substudy: A phase II study of sotorasib in participants (Pts) with previously treated stage IV or recurrent KRAS G12C mutant non-squamous (Non-sq) non-small cell lung cancer (NSCLC).
Authors
Sukhmani Kaur Padda
Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA
Sukhmani Kaur Padda , Mary Weber Redman , David E Gerber , Tom Stinchcombe , Saiama Naheed Waqar , Ticiana Leal , Katherine Minichiello , Karen L. Reckamp , Roy S. Herbst , Hossein Borghaei , Julie R. Brahmer , Jhanelle Elaine Gray , Karen Kelly , Suresh S. Ramalingam , Joel W. Neal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT04625647
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS9143)
DOI
10.1200/JCO.2023.41.16_suppl.TPS9143
Abstract #
TPS9143
Poster Bd #
129a
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
S1507: Phase II study of docetaxel and trametinib in patients with G12C or non-G12C KRAS mutation positive (+) recurrent non-small cell lung cancer (NSCLC).
First Author: Shirish M. Gadgeel
Poster
2023 ASCO Annual Meeting
Clinical and genomic predictors of response and toxicity to sotorasib in a real-world cohort of patients with advanced KRAS G12C-mutant non-small cell lung cancer.
First Author: Kathryn C. Arbour
Poster
2023 ASCO Annual Meeting
The impact of PD-L1 expression and co-mutations on outcome of KRAS-driven non-small-cell lung cancer.
First Author: Petros Christopoulos
Poster
2020 ASCO Virtual Scientific Program
Phase II study of TAK228 in patients with advanced non-small cell lung cancer (NSCLC) harboring NFE2L2 and KEAP1 mutations.
First Author: Paul K. Paik